Biopsy of a Small Kidney Mass: When It Helps, and When It Does Not

နောက်ဆုံး ပြင်ဆင်သည် ဩဂုတ် 28, 2026

• တော်သေးတယ်။
• LinkedIn
• မေးလ်

Kidney cancer is usually silent, and most kidney masses today are found by accident — on a scan done for something else, or as part of a health-check package. A small renal mass means a solid kidney lesion under four centimetres, and it presents a genuine dilemma: it might be cancer, and it might not.

Broadly, around eight in ten turn out to be malignant and two in ten benign — with the benign proportion higher the smaller the lesion. Removing all of them means operating on a substantial number of people who never needed it, which is the problem biopsy was introduced to solve.

• ထိုင်းနိုင်ငံ ဆီးလမ်းကြောင်းဌာန ဘန်ကောက်ဆေးရုံ အွန်လိုင်းဘွတ်ကင်လုပ်ခြင်း။ 02-310-3009 bhquro@bdms.co.th
• Samitivej Sriracha ဆေးရုံ Chonburi 088-022-1445

The question is not whether biopsy is possible

It is whether the result would change anything. That principle was implied in the earlier version of this article and is worth stating outright, because it decides who should have one.

Where a biopsy earns its place

• Before ablation — freezing or heating the tumour destroys it without producing a specimen, so the diagnosis has to be made beforehand.
• Where surgery would be a serious undertaking — an older patient, significant heart or lung disease, one kidney, or poor kidney function. Knowing whether the lesion is benign changes whether the risk is worth taking.
• Where surveillance is being considered rather than treatment, and the patient wants to know what is being watched.
• Where the mass might not be a primary kidney cancer at all — lymphoma, or a deposit from a cancer elsewhere, both of which are treated by an oncologist rather than a surgeon.

Where it can reasonably be skipped — absent from the earlier version

• A fit patient with a clearly suspicious mass who is proceeding to surgery anyway. The operation provides the diagnosis, and a biopsy adds a procedure without changing the plan.
• A mass containing visible fat on CT, which is characteristic enough of a benign angiomyolipoma that a needle is not needed.
• Predominantly cystic lesions, which biopsy samples poorly and which are assessed and followed on imaging instead.

What the procedure involves

You lie face down, local anaesthetic is injected over the flank, and two or three tissue cores are taken with a fine needle guided by ultrasound or CT. It is an outpatient procedure, usually with a period of observation afterwards.

Access is harder where there is a lot of body fat between skin and kidney, and posterior masses are easier to reach than those at the front. Blood-thinning medication has to be discussed and usually paused beforehand — this is a needle into a highly vascular organ, and that discussion was missing from the earlier version. Do not stop such medication on your own; the timing is arranged with the prescriber.

The limitation that matters most

The earlier version quoted an accuracy of up to 92% and a complication rate under 2%. Both figures are fair. What was missing is the number patients actually need.

Roughly one biopsy in ten comes back non-diagnostic — not benign, not malignant, simply not enough usable tissue to say. The 92% figure describes how accurate the answer is when there is an answer; it is not the chance of getting one. A non-diagnostic result usually leads to a repeat biopsy, and the second attempt is often successful.

And the consequence that follows: a non-diagnostic biopsy does not mean the mass is benign. A suspicious lesion with an inconclusive biopsy is still a suspicious lesion, and is managed as one.

Risks

• Bleeding around the kidney — the commonest, usually minor and self-limiting, occasionally requiring transfusion or a procedure to stop it.
• Blood in the urine and flank pain, generally settling within days.
• Air in the chest cavity, uncommon, and relevant for upper-pole masses close to the lung.
• Tumour spreading along the needle track — a long-standing worry that modern technique has reduced to something close to negligible. It is worth mentioning precisely because patients ask, and the honest answer reassures.

What happens with the result

If it shows cancer

The options are surgery — removing the tumour and sparing the rest of the kidney where possible — ablation, or active surveillance. That last one deserves more than a mention in a list, because it is frequently the right answer and patients rarely expect it: many small kidney cancers grow very slowly, and in an older person with other conditions, watching a small tumour on scans is often safer than operating on it. The biopsy result and the grade help decide which.

If it shows a benign mass — a correction

The earlier version said that a benign result leads to surveillance, with repeat biopsy considered if the mass exceeds 4 cm or grows faster than 5 mm a year. Those thresholds are the triggers for reconsidering treatment during surveillance, not for repeating a biopsy, and the statement has been rewritten.

What actually follows depends on which benign diagnosis it is — they behave differently and are followed differently. And the point behind the confusion is worth keeping: a benign biopsy is reassuring rather than final. A needle samples part of a lesion, so a mass that continues to enlarge is reassessed regardless of what the first biopsy said. Surveillance is not discharge.

Symptoms that need attention the same day

In an emergency in Thailand, call 1669.

• After a biopsy: severe or worsening flank pain, heavy bleeding or clots in the urine, dizziness, breathlessness or a racing pulse, or fever.
• Visible blood in the urine that has not been investigated — see blood in the urine.
• A mass you can feel in the abdomen or flank, or persistent flank pain with weight loss or fevers.
• New swelling of the legs, or a varicocele appearing on the right side — see varicocele, where this is explained as a reason to image the abdomen.
• A scan report mentioning a kidney lesion that was never followed up. Not urgent today, and the item most likely to matter.

Frequently Asked Questions About Kidney Mass Biopsy

Do I need a biopsy of my kidney mass?

Only if the result would change what happens next. It is valuable before ablation, where surgery carries significant risk, where surveillance is being considered, or where the mass might not be a primary kidney cancer. A fit patient proceeding to surgery anyway, a mass containing fat on CT, and predominantly cystic lesions can reasonably skip it.

How accurate is it?

Highly accurate when it yields an answer — up to around 92%. What matters alongside that is that roughly one biopsy in ten is non-diagnostic, meaning not enough usable tissue to say either way. That usually leads to a repeat, and a non-diagnostic result does not mean the mass is benign.

Is it safe? Could the needle spread the cancer?

Complications occur in under 2% and are mostly bleeding around the kidney, blood in the urine and flank pain, almost always settling on their own. Spread along the needle track was a genuine historical concern and modern technique has reduced it to something close to negligible. Blood-thinning medication is reviewed beforehand.

The biopsy showed a benign mass. Am I discharged?

No. A needle samples part of a lesion, so a benign result is reassuring rather than final, and follow-up imaging continues. What that follow-up looks like depends on which benign diagnosis it is. A mass that keeps growing is reassessed regardless of the first result.

If it is cancer, does it have to be removed?

Not necessarily. Many small kidney cancers grow very slowly, and in an older person with other medical conditions, monitoring a small tumour on scans is often safer than operating. Surgery, ablation and active surveillance are all legitimate options, and the biopsy result helps decide between them.

Arranging a consultation

Dr. Soarawee Weerasopone sees patients at ဘန်ကောက်ဆေးရုံ